Texas Biomedical Research Institute
Texas Biomedical Research Institute (Texas Biomed) is a leading nonprofit biomedical research organization with more than 80 years of experience supporting the development of medical countermeasures for emerging and high-consequence infectious diseases. Texas Biomed provides comprehensive in-vitro and in-vivo preclinical research services supporting the discovery, development, and evaluation of vaccines, therapeutics, diagnostics, and other medical countermeasures from early discovery through preclinical proof-of-concept, efficacy, and translational research. Studies can be conducted under GLP or GLP-like quality frameworks, as appropriate to program stage and sponsor requirements, with integrated quality assurance and study compliance support. The Institute operates state-of-the-art ABSL-2, ABSL-3, as well as the only privately operated BSL-4 research facilities, together with the Southwest National Primate Research Center, enabling studies in small animal and nonhuman primate models under high-containment conditions. Texas Biomed has extensive expertise in virus propagation and characterization, antiviral and neutralization assays, molecular diagnostics, immunology, pathology, bioinformatics, animal model development, natural history studies, efficacy testing, pharmacology, and biomarker evaluation across a broad range of viral pathogens, including filoviruses, henipaviruses, arenaviruses, alphaviruses, flaviviruses, coronaviruses, hantaviruses, and other emerging and biodefense-relevant viruses. Pathogen expertise includes, but is not limited to, Ebola virus (EBOV), Sudan virus (SUDV), Bundibugyo virus (BDBV), Marburg virus (MARV), Nipah virus (NiV), Lassa virus (LASV), Junín virus (JUNV), Machupo virus (MACV), Western equine encephalitis virus (WEEV), Japanese encephalitis virus (JEV), West Nile virus (WNV), Dengue virus (DENV) and SARS-CoV-2. With decades of experience supporting Animal Rule programs and infectious disease research, Texas Biomed delivers integrated, high-quality preclinical solutions for government, industry, and academic partners developing medical countermeasures for BSL-2, BSL-3, and BSL-4 pathogens.
Industries
Nr. of Employees
large (251-1000)
Texas Biomedical Research Institute
P.O. Box 760549, San Antonio, TX 78245-0549
Patents
Cell culture media and methods for generating human alveolar macrophage-like cells
2024-12-24 • US-12173326-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
2020-08-25 • US-10751406-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
2017-08-15 • US-9730996-B2
View Details
Cell culture media and methods for generating human alveolar macrophage-like cells
2024-12-24 • US-12173326-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
2020-08-25 • US-10751406-B2
View DetailsInvolucrin-driven retroviral expression cassettes encoding human immunodeficiency virus envelope glycoproteins
2017-08-15 • US-9730996-B2
View DetailsProducts
CoDe: codon deoptimization tool
Computational tool to recode RNA/DNA sequences via codon-pair deoptimization to attenuate viruses by increasing underrepresented codon pairs without altering amino acid sequences.
Meta-Transcriptome Detector (MTD) pipeline
Bash-executed pipeline for joint analysis of host transcriptome and microbiome using bulk and single-cell RNA-seq; generates count matrices, graphs and summary outputs.
Cell culture media and methods for generating alveolar macrophage–like cells
In vitro differentiation protocol using a surfactant and cytokine mixture to convert blood-derived monocytes into alveolar macrophage–like cells that retain phenotype and function for extended culture.
Involucrin-driven retroviral expression cassette vaccine platform
Vaccine platform using differentiation-specific transcriptional regulatory elements to direct antigen expression in epithelial stem cell lineages for mucosal antigen presentation.
Monoclonal antibodies and antigen-binding fragments for SARS-CoV-2
Human monoclonal antibodies and fragments with broad neutralizing activity described for therapeutic use against SARS-CoV-2 infections.
Compositions and methods for treating Schistosoma infections
Patent-disclosed composition(s) and methods intended to treat Schistosoma infections.
CoDe: codon deoptimization tool
Computational tool to recode RNA/DNA sequences via codon-pair deoptimization to attenuate viruses by increasing underrepresented codon pairs without altering amino acid sequences.
Meta-Transcriptome Detector (MTD) pipeline
Bash-executed pipeline for joint analysis of host transcriptome and microbiome using bulk and single-cell RNA-seq; generates count matrices, graphs and summary outputs.
Cell culture media and methods for generating alveolar macrophage–like cells
In vitro differentiation protocol using a surfactant and cytokine mixture to convert blood-derived monocytes into alveolar macrophage–like cells that retain phenotype and function for extended culture.
Involucrin-driven retroviral expression cassette vaccine platform
Vaccine platform using differentiation-specific transcriptional regulatory elements to direct antigen expression in epithelial stem cell lineages for mucosal antigen presentation.
Monoclonal antibodies and antigen-binding fragments for SARS-CoV-2
Human monoclonal antibodies and fragments with broad neutralizing activity described for therapeutic use against SARS-CoV-2 infections.
Compositions and methods for treating Schistosoma infections
Patent-disclosed composition(s) and methods intended to treat Schistosoma infections.
Expertise Areas
- Infectious disease preclinical research
- Rodent and Nonhuman primate model development and management
- Vaccine and therapeutic discovery and preclinical development
- Monoclonal antibody discovery and characterization
Key Technologies
- Biosafety level 4 (BSL-4) operations
- Biosafety level 3 (BSL-3) operations
- Nonhuman primate (NHP) models
- Telemetry for animal studies
Key People
Bruce Edwards
Executive Vice President, Finance & Administration and Chief Financial Officer
Dr. Cory Hallam
Executive Vice President, Applied Science and Innovation
Dr. Corinna Ross
Director, Southwest National Primate Research Center
Bruce Edwards
Executive Vice President, Finance & Administration and Chief Financial Officer
Dr. Cory Hallam
Executive Vice President, Applied Science and Innovation
Dr. Corinna Ross
Director, Southwest National Primate Research Center
News & Updates
Australian antiviral drug development company, Island Pharmaceuticals Ltd has executed a Statement of Work with Texas Biomedical Research Institute to further advance Galidesivir’s Animal Rule development for the treatment of Marburg Virus Disease.
Texas Biomed has signed a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of War (DoW) to help protect service members and civilians from emerging and high-consequence biological threats.
The Southwest National Primate Research Center, a national leader in biomedical research and primate care, has been awarded a renewed P51 base grant by the National Institutes of Health (NIH). The grant will fund research, infrastructure, animal care and veterinary services that enable innovation in human and animal health.
Texas Biomedical Research Institute Assistant Professor Riti Sharan, Ph.D., has received a $4.5 million R01 grant from the National Institutes of Health to study a promising immunotherapy for individuals affected by HIV and tuberculosis.
Texas Biomed is working with its global partners to test therapies and preventatives for the ongoing outbreak caused by the virus in the Democratic Republic of the Congo (DRC) and Uganda.
Existing treatments for tuberculosis (TB) and HIV control the pathogens, but the immune system does not revert to normal, according to research by Texas Biomed and collaborators.
Australian antiviral drug development company, Island Pharmaceuticals Ltd has executed a Statement of Work with Texas Biomedical Research Institute to further advance Galidesivir’s Animal Rule development for the treatment of Marburg Virus Disease.
Texas Biomed has signed a new Cooperative Research and Development Agreement (CRADA) with the U.S. Department of War (DoW) to help protect service members and civilians from emerging and high-consequence biological threats.
The Southwest National Primate Research Center, a national leader in biomedical research and primate care, has been awarded a renewed P51 base grant by the National Institutes of Health (NIH). The grant will fund research, infrastructure, animal care and veterinary services that enable innovation in human and animal health.
Texas Biomedical Research Institute Assistant Professor Riti Sharan, Ph.D., has received a $4.5 million R01 grant from the National Institutes of Health to study a promising immunotherapy for individuals affected by HIV and tuberculosis.
Texas Biomed is working with its global partners to test therapies and preventatives for the ongoing outbreak caused by the virus in the Democratic Republic of the Congo (DRC) and Uganda.
Existing treatments for tuberculosis (TB) and HIV control the pathogens, but the immune system does not revert to normal, according to research by Texas Biomed and collaborators.